DCAF17

Across TCGA pan-cancer cohorts, DCAF17 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCAF17 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher DCAF17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCAF17 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

CESC, STAD, and LIHC are the cancer types where DCAF17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.091	0.728	<.001	26	view →
STAD	OS	Median	All	0.184	0.730	.001	18	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
LUAD	OS	Median	All	0.338	0.834	.004	6	view →
SKCM	DFS	Median	All	1.000	0.195	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCAF17–CESC (DFS)

Open the CESC breakdown →